Safe Migraine Medications During Pregnancy: What Is Approved, What to Avoid, and Why

Migraine during pregnancy creates a clinical situation that requires careful navigation. Most migraine medications have not been tested in pregnant populations through randomized controlled trials, because such trials would raise serious ethical concerns. This means that the safety data for most migraine treatments in pregnancy comes from observational studies, case reports, and animal research rather than the gold standard of controlled clinical evidence. The result is an evidence base that is less complete than patients and clinicians would prefer.

Despite these limitations, a practical and reasonably evidence-informed approach to migraine treatment during pregnancy is possible. Some medications have sufficient safety data to support their use in pregnancy. Others carry known risks. And a range of non-pharmacological approaches can reduce medication burden while still providing meaningful relief.

The Challenge of Migraine in Pregnancy

Approximately seventy percent of women with migraine experience improvement in attack frequency during the second and third trimesters of pregnancy, when estrogen levels are sustained at high and stable levels. For many women, migraine becomes less of an active management problem after the first trimester, though the first trimester itself can be a period of worsened migraine as hormone levels rise and fluctuate.

For women who continue to have frequent or severe attacks throughout pregnancy, the treatment question is clinically important. Uncontrolled severe migraine during pregnancy is associated with its own risks including dehydration, poor nutrition intake, increased stress, and sleep disruption. The goal of treatment is not zero medication use but appropriate, proportionate management that weighs the risks of medication against the risks of untreated severe migraine.

Acute Medications Considered Safer in Pregnancy

Acetaminophen is generally considered the safest over-the-counter pain reliever during pregnancy and is the first-line option for acute migraine treatment. It does not carry the risks associated with nonsteroidal anti-inflammatory drugs and has a long history of use in pregnancy.

Nonsteroidal anti-inflammatory drugs including ibuprofen and naproxen are generally acceptable in the first trimester but should be avoided in the third trimester due to risks of premature closure of the ductus arteriosus, a blood vessel in the fetal heart. Many clinicians also recommend limiting their use in the second trimester.

Triptans are the most effective acute migraine medications for most people, but their use in pregnancy requires individualized discussion with a healthcare provider. The largest observational datasets on triptan use in pregnancy have not demonstrated clear evidence of major congenital malformations, but the evidence is incomplete and guidelines vary. Sumatriptan has the largest safety dataset among triptans in pregnancy and may be considered in cases where acetaminophen is insufficient and the migraine is severe.

Medications to Avoid in Pregnancy

Ergotamine and dihydroergotamine are contraindicated in pregnancy due to their vasoconstrictive effects on uterine blood vessels, which can reduce fetal blood supply.

Valproate, a preventive medication used for migraine, is teratogenic and associated with significant risks of fetal neural tube defects and developmental delay. It is contraindicated in pregnancy and should not be used in women of childbearing potential without highly reliable contraception and careful risk discussion.

Topiramate, another preventive medication, is associated with an increased risk of oral cleft in the newborn and reduced fetal growth. Its use in pregnancy requires careful risk-benefit discussion.

Preventive Approaches in Pregnancy

For women who need preventive migraine treatment during pregnancy, the options are more limited than outside pregnancy. Magnesium supplementation, which has evidence as a migraine preventive and is also sometimes used in obstetric care, is generally considered safe in pregnancy at appropriate doses and may be discussed with an OB provider.

Propranolol, a beta-blocker used in migraine prevention, has been used in pregnancy in other contexts including the treatment of hypertension and has a more established pregnancy safety profile than most other migraine preventives. Its use for migraine prevention in pregnancy requires individualized assessment.

The Importance of Working With an OB Provider

Migraine management during pregnancy is a conversation that should involve both the treating neurologist or headache specialist and the obstetric provider. These two providers bring complementary expertise, and coordination between them produces better outcomes than managing the two aspects of care separately.

Women who are planning pregnancy and currently taking migraine preventive medications should discuss medication safety before conception, when possible, to allow time for transitions to safer alternatives if needed.